Literature DB >> 16147535

CAMPATH: from concept to clinic.

Herman Waldmann1, Geoff Hale.   

Abstract

Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity diseases.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16147535      PMCID： PMC1569536          DOI： 10.1098/rstb.2005.1702

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN： 0962-8436            Impact factor:   6.237


  48 in total

Review 1.  Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Authors:  G Hale; S Slavin; J M Goldman; S Mackinnon; S Giralt; H Waldmann
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

2.  Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.

Authors:  P R Rebello; G Hale; P J Friend; S P Cobbold; H Waldmann
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

3.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors:  Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

Authors:  José A Pérez-Simón; Panagiotis D Kottaridis; Rodrigo Martino; Charles Craddock; Dolores Caballero; Raj Chopra; Javier García-Conde; Don W Milligan; Stephen Schey; Alvaro Urbano-Ispizua; Anne Parker; Angel Leon; Kwee Yong; Ana Sureda; Ann Hunter; Jordi Sierra; Anthony H Goldstone; David C Linch; Jesus F San Miguel; Stephen Mackinnon
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

Authors:  A J Coles; M Wing; S Smith; F Coraddu; S Greer; C Taylor; A Weetman; G Hale; V K Chatterjee; H Waldmann; A Compston
Journal:  Lancet       Date:  1999-11-13       Impact factor: 79.321

6.  In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.

Authors:  P D Kottaridis; D W Milligan; R Chopra; R K Chakraverty; S Chakrabarti; S Robinson; K Peggs; S Verfuerth; R Pettengell; J C Marsh; S Schey; P Mahendra; G J Morgan; G Hale; H Waldmann; M C Ruiz de Elvira; C D Williams; S Devereux; D C Linch; A H Goldstone; S MacKinnon
Journal:  Cytotherapy       Date:  2001       Impact factor: 5.414

7.  CAMPATH-1 antibodies in stem-cell transplantation.

Authors:  G Hale; S Cobbold; N Novitzky; D Bunjes; R Willemze; H G Prentice; D Milligan; S MacKinnon; H Waldmann
Journal:  Cytotherapy       Date:  2001       Impact factor: 5.414

8.  Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Authors:  Allan D Kirk; Douglas A Hale; Roslyn B Mannon; David E Kleiner; Steven C Hoffmann; Robert L Kampen; Linda K Cendales; Douglas K Tadaki; David M Harlan; S John Swanson
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

9.  The use of Campath-1H as induction therapy in renal transplantation: preliminary results.

Authors:  Gaetano Ciancio; George W Burke; Jeffrey J Gaynor; Adela Mattiazzi; Ramin Roohipour; Manuel R Carreno; David Roth; Phillip Ruiz; Warren Kupin; Anne Rosen; Violet Esquenazi; Andreas G Tzakis; Joshua Miller
Journal:  Transplantation       Date:  2004-08-15       Impact factor: 4.939

10.  Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation.

Authors:  Andreas G Tzakis; Panagiotis Tryphonopoulos; Tomoaki Kato; Seigo Nishida; David M Levi; Juan R Madariaga; Jeffrey J Gaynor; Werviston De Faria; Arie Regev; Violet Esquenazi; Debbie Weppler; Phillip Ruiz; Joshua Miller
Journal:  Transplantation       Date:  2004-04-27       Impact factor: 4.939
View more
  26 in total

Review 1.  Have we overestimated the benefit of human(ized) antibodies?

Authors:  Daniel R Getts; Meghann T Getts; Derrick P McCarthy; Emily M L Chastain; Stephen D Miller
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

2.  Introduction: immunoregulation: harnessing T cell biology for therapeutic benefit.

Authors:  Su M Metcalfe; Roy Y Calne; Stephen P Cobbold
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

3.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Authors:  Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

4.  Alemtuzumab in allogeneic hematopoetic stem cell transplantation.

Authors:  Xavier Poiré; Koen van Besien
Journal:  Expert Opin Biol Ther       Date:  2011-06-27       Impact factor: 4.388

Review 5.  In search of magic bullets: the golden age of immunotherapeutics.

Authors:  John J O'Shea; Yuka Kanno; Andrew C Chan
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

6.  Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.

Authors:  Kamal Sharma; John E Janik; Deirdre O'Mahony; Donn Stewart; Stefania Pittaluga; Maryalice Stetler-Stevenson; Elaine S Jaffe; Mark Raffeld; Thomas A Fleisher; Cathryn C Lee; Seth M Steinberg; Thomas A Waldmann; John C Morris
Journal:  Clin Cancer Res       Date:  2016-08-02       Impact factor: 12.531

7.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 8.  Alemtuzumab for the prevention and treatment of graft-versus-host disease.

Authors:  Junya Kanda; Richard D Lopez; David A Rizzieri
Journal:  Int J Hematol       Date:  2011-03-03       Impact factor: 2.490

9.  Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Authors:  Liuyan Jiang; Constance M Yuan; Julia Hubacheck; John E Janik; Wyndham Wilson; John C Morris; Gregory A Jasper; Maryalice Stetler-Stevenson
Journal:  Br J Haematol       Date:  2009-02-19       Impact factor: 6.998

10.  Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.

Authors:  Thomas Neumann; Laila Schneidewind; Thomas Thiele; Meike Schulze; Anne F Klenner; Christoph Busemann; Daniel Pink; Andreas Greinacher; Gottfried Dölken; William H Krüger
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-16       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.